Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences

Vaccine

Volumn 33, Issue 36, 2015, Pages 4406-4413

  Pabst, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Intranasal vaccination; Nasal mucosa; Nose associated lymphoid tissue (NALT); Species differences

Indexed keywords

ADJUVANT; ALLERGEN; CELL ADHESION MOLECULE; VACCINE;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BACTERIUM; CHINCHILLA; DENDRITIC CELL; FARM ANIMAL; HUMAN; IMMUNITY; INFECTION; LYMPHOCYTE SUBPOPULATION; LYMPHOID ORGAN; LYMPHOID TISSUE; MOUSE; MUCOSAL VACCINATION; NONHUMAN; NOSE ASSOCIATED LYMPHOID TISSUE; NOSE MUCOSA; PEYER PATCH; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS; ANIMAL; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; NOSE; RODENT;

ADMINISTRATION, INTRANASAL; ANIMALS; HUMANS; LYMPHOID TISSUE; NASAL MUCOSA; NOSE; RODENTIA; VACCINES;

EID: 84939568357     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.07.022     Document Type: Review

References (78)

1. Holmgren J., Lycke N. Principles of mucosal vaccine strategies. Principles of mucosal immunology 2013, 413-428. Garland Science, London. P.D. Smith, T.T. Mac Donald, R.S. Blumberg (Eds.).
2. Fukuyama Y., Tokuhara D., Kataoka K., Gilbert R.S., McGhee J.R., Yuki Y., et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines 2012, 11:367-379.
3. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 2012, 12:592-605.
4. Kunkel E.J., Bucher E.C. Plasma-cell homing. Nat Immunol 2003, 3:822-829.
5. Brandtzaeg P., Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004, 25:570-577.
6. Brandtzaeg P., Kiyono H., Pabst R., Russel M.W. Terminology: nomenclature of mucosa-associated lymphoid tissue. Mucosal Immunol 2008, 1:31-37.
7. Czerzinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immun 2012, 354:1-18.
8. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
9. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 1992, 13:219-224.
10. Kraal G. Nasal-associated lymphoid tissue. Mucosal immunology. 1 2005, 415-422. Academic Press, Amsterdam. 3rd ed. J. Mestecky, M.E. Lamm, W. Strober, J. Bienenstock, J.R. McGhee, L. Mayer (Eds.).
11. Kiyono H. The nasopharyngeal and oral immune system. Principles of mucosal immunology 2013, 293-306. Garland Sciences, London. P.D. Smith, T.T. Mac Donald, R.S. Blumberg (Eds.).
12. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Contr Release 2003, 87:187-198.
13. Sharma S., Muhkut T.S.K., Bearson H.A.E., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharmaceut Syst 2009, 98:812-843.
14. Seitz M., Beinecke A., Seele J., Fulde M., Valentin-Weigand P., Baums C.G. A novel intranasal mouse model for mucosal colonisation of Streptococcus suis serotype 2. J Med Microbiol 2012, 61:1311-1318.
15. Baumann U. Mucosal vaccination against bacterial respiratory infections. Expert Rev Vaccines 2008, 7:1257-1276.
16. Henriksson G., Hegeland L., Midtvedt T., Stierna P., Brandtzaeg P. Immune response to Mycoplasma pulmonis in nasal mucosa is modulated by normal microbiota. Am J Respir Cell Mol Biol 2004, 31:657-662.
17. Beverly P.C.L., Sridhar S., Lalvani H., Tchilian E.Z. Harnessing local and systemic immunity for vaccines against tuberculosis. Mucosal Immunol 2014, 7:20-26.
18. Czerkinsky C., Holmgren J. Topical immunization strategies. Mucosal Immunol 2010, 3:545-555.
19. Kunisawa J., Nochi T., Kiyono H. Immunological commonalities and distinctions between airway and digestive immunity. Trends Immunol 2008, 29:505-513.
20. Keitel W.A., Cate T.R., Nino D., Huggins C.L., Six H.R., Quarks J.M., Couate R.B. Immunization against influenza: comparison of various topical and parental regimens containing inactivate and/or live attenuate vaccines in healthy adults. J Infect Dis 2001, 183:329-332.
21. Rose M.A., Zielen S., Baumann U. Mucosal immunity and nasal influenza vaccination. Expert Rev Vaccines 2012, 11:595-607.
22. Baumann U., Göcke K., Gewecke B., Freihorst J., von Specht B.U. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study. Respir Res 2007, 8:57-67.
23. Arnold H., Bumann D., Felies M., Gewecke B., Sörensen M., Gessner J.E., et al. Enhanced immogenicity in the murine airway mucosa with an attenuated salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa. Infect Immun 2004, 72:6546-6553.
24. Larbig M., Mansouri E., Freihorst J., Tümmler B., Kohler G., Domedey H., et al. Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Vaccine 2001, 19:2291-2297.
25. Göcke K., Baumann U., Hagemann H., Gabelsberger J., Hahn H., Freihorst J., von Specht B.U. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. mucosal booster schedule. TEMS Immunol Med Microbiol 2003, 37:167-171.
26. Bumann D., Behre C., Behre K., Herz S., Gewecke B., Gessner J.E., et al. Systemic, nasal and live vaccines against Pseudomonas aeruginosa: clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 2009, 28:707-713.
27. Vajdy M., Singh M. Intranasal delivery of vaccines against HIV. Expert Opin Drug Deliv 2006, 3:247-259.
28. Lynch J.P., Zhanell G.G. Streptococcus pneumonia: epidemiology and risk factors, evolution of antimicrobial resistance, and the impact of vaccines. Curr Opin Pulm Med 2010, 16:217-225.
29. Fujihashi K., Kiyono H. The nasopharyngeal and oral immune system. Principles of mucosal immunology 2013, 293-306. Garland Sciences, London. P.D. Smith, T.T. MacDonald, R.S. Blumberg (Eds.).
30. Illum L. Nasal clearance in health and disease. J Aerosol Med 2006, 19:92-99.
31. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Eng J Med 2004, 350:896-903.
32. Illum L. Nasal drug delivery-possibilities problems and solutions. J Control Release 2003, 87:187-198.
33. Nazareth L., Lineburg K.E., Chuah M.I., Tello Velasquez J., Chehrehasa F, St John J.A., et al. Olfactory ensheathing cells are the main phagocytic cells that remove axon debris during early development of the olfactory system. J Comp Neurol 2015, 532:479-494.
34. Harris J.A., West A.K., Chuah M.I. Olfactory ensheathing cells: nitric oxide production and innate immunity. Glia 2009, 57:1848-1857.
35. Wewetzer K., Radtke C., Kocsis J., Baumgärtner W. Species-specific control of cellular proliferation and the impact of large animal models for the use of olfactory ensheathing cells and Schwann cells in spinal cord repair. Exp Neurol 2011, 229:80-87.
36. Kalinke U., Bechmann I., Detje C.N. Host strategies against virus entry via the olfactory system. Virulence 2011, 2:367-370.
37. Brandes G., Khayami M., Peck C.T., Baumgärnter W., Bugday H., Wewetzer K. Cell surfaxe expression of 27C7 neonatal rat olfactory ensheathing cells in situ and in vitro is independent of axonal contact. Histochem Cell Biol 2011, 135:397-408.
38. Spit B.J., Hendricksen E.G., Bruijntjes J.P., Kuper C.F. Nasal lymphoid tissue in the rat. Cell Tissue Res 1989, 255:193-198.
39. Kuper C.F. Histopathology of mucosa-associated lymphoid tissue. Toxicol Pathol 2006, 34:609-619.
40. Hameleers D.M., van der Ende M., Biewenga J., Sminia T. An immunohistochemical study on the postnatal development of rat nasal-associated lymphoid tissue (NALT). Cell Tissue Res 1989, 256:431-438.
41. van der Ven I., Sminia T. The development and structure of mouse nasal-associated lymphoid tissue: an immune- and enzyme-histochemical study. Res Immunol 1993, 5:69-75.
42. Kuper C.F., van Oostrum L., Ma-Hock L., Durrer S. Woutersen RA. Hyperplasia of the lymphoepithelium of NALT in rats but not in mice after 28-day exposure to 15ppm formaldehyde vapor. Exp Toxicol Pathol 2011, 63:25-32.
43. Oros-Pantoja R., Jarillo-Luna S., Rivera-Aguilar V., Sánches-Torres L.E., Godinez-Victoria M., Campos-Rodriguez R. Effects of restraint stress on NALT structure and nasal IgA levels. Immunol Lett 2011, 135:78-87.
44. Park H.S., Francis K.P., Yu J., Cleery P.R. Membranous cells in nose-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus. J Immunol 2003, 171:2432-2537.
45. Krege J., Seth S., Hardtke S., Davalos-Misslitz A.C.M., Förster R. Antigen dependent rescue of nose-assoviated lymphoid tissue (NALT) development independent of LTßR and CXCR5 signaling. Eur J Immunol 2009, 39:2765-2778.
46. Csencsits K.L., Jutila M.A., Pascual D.W. Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur J Immunol 2002, 32:3029-3039.
47. Ohmichi Y., H.Irakawa J., Imai J., Fukuda M., Kawashima H. Essential role of peripheral node addressin in lymphocyte homing nasal-associated lymphoid tissues and allergic immune responses. J Exp Med 2011, 208:1015-1025.
48. Heritage P.L., Underdown B.J., Arsenault A.L., Snider D.P., McDermott M.R. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Am J Respir Crit Care Med 1997, 156:1256-1262.
49. Asanuma H., Thompson A.H., Iwasak T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. J Immunol Methods 1997, 202:123-134.
50. Asanuma H., Aizawa C., Kurata T., Tamura S.I. IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccination by intranasal, intravenous and/or subcutaneous administration. Vaccine 1998, 16:1257-1262.
51. Brandtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. Immunol Invest 2010, 39:303-355.
52. Shikina T., Hiroi T., Iwatani K., Jang M.H., Fukuyama S., Tamura M., et al. IgA class switch occurs in the organized nasopharynx- and gut-associated lymphoid tissue, but not in the diffuse lamina propria of airways and gut. J Immunol 2004, 172:6259-6264.
53. Fernandez S., Cisney E.D., Hall S.I., Ulrich R.G. Nasal immunity to Staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue. Clin Vaccine Immunol 2011, 18:667-675.
54. Cisney E.D., Fernandez S., Hall S.I., Krietz G.A., Ulrich R.G. Examining the role of nasopharyngeal-associated lymph reticular tissue (NALT) in mouse responses to vaccines. J Visual Exper 2012, 66:3960. 10.3791/3960.
55. Jurcisek J.A., Durbin J.E., Kusewitt D.F., Bakaletz L.O. Anatomy of the nasal cavity in the chinchilla. Cells Tissues Organs 2003, 174:136-152.
56. Novotny L.A., Clements J.D., Bakaletz L.O. Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to non-typeable Haemophilus influenzae. Mucosal Immunol 2011, 4:456-467.
57. Pereira M., Marci N.P., Creasy D.M. Evaluation of the rabbit nasal cavity in inhalation studies and a comparison with other common laboratory species and man. Toxicol Pathol 2011, 39:893-900.
58. Liebler-Tenorio E.M., Pabst R. MALT structure and function in farm animals. Vet Res 2006, 37:257-280.
59. Casteleyn C., Breugelmans S., Simoens P., van den Broeck W. The tonsils revisited: review of the anatomical localization and histological characteristics of the tonsils of domestic and laboratory animals. Clin Dev Immunol 2011, 1-14. 10.1155/2011/472460.
60. Debertin A.S., Tschernig T., Tönjes H., Kleemann W.J., Tröger H.D., Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin Exp Immunol 2003, 134:503-507.
61. Fujimura Y. Evidence of M cells as portal of entry for antigens in the nasopharyngeal lymphoid tissue of humans. Virchows Arch 2000, 436:560-566.
62. Sabirov A., Metzger D.W. Intranasal vaccination of infant mice induces protection immunity in the absence of nasal-association lymphoid tissue. Vaccine 2008, 26:1566-1576.
63. Wiley J.A., Tighe M.P., Harmsen A.G. Upper respiratory tract resistance to influenza infection is not prevented by absence of either nasal-associated lymphoid tissue or cervical lymph nodes. J Immunol 2005, 175:3186-3196.
64. Ronan E.O., Lee L.N., Tchilian E.Z., Beverley P.C. Nasal associated lymphoid tissue (NALT) contributes little to protection against aerosol challenge with Mycobacterium tuberculosis after immunisation with a recombinant adenoviral vaccine. Vaccine 2010, 28:5179-5184.
65. Kim D.Y., Sato A., Fukuyama S., Sagara H., Nagatake T., Kong I.G., et al. The airway antigen sampling system: respiratory M cells as an alternative gateway for inhaled antigens. J Immunol 2011, 186:4253-4262.
66. Schon-Hegrad M.A., Oliver J., McMenamin P.G., Holt P.J. Studies on the density, distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic cells (DC) in the conducting airways. J Exp Med 1991, 173:1345-1356.
67. Jahnsen F.L., Gran E., Haye R., Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. Am J Respir Cell Mol Biol 2004, 30:31-37.
68. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., Mc Glee J.R. Effective mucosal immunity to Antrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003, 170:5636-5643.
69. Zuercher A.W., Horn M.P., Wu H., Song Z., Bundgaard C.J., Johansen H.K., et al. Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa. Vaccine 2006, 24:4333-4342.
70. Zanvit P., Tichopad A., Havlickova M., Novotna O., Jirkovska M., Kolostova K., et al. Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A. Immunol Lett 2010, 134:26-34.
71. Noda K., Kodama S., Umemoto S., Abe N., Hirano T., Suzuki M. Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces non-typeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine 2010, 28:5068-5074.
72. Hagenaars N., Mania M., de Jong P., Que I., Nieuwland R., Slütter B., et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 2010, 144:17-24.
73. Berstad A.K., Andersen S.R., Dalseg R., Dromtorp S., Holst J., Namork E., et al. Inactivated meningococci and pertussis bacteria are immunogenetic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine. Vaccine 2000, 18:1910-1919.
74. Fukuyama Y., Tokuhara D., Sekine S., Kataoka U., Markham J.D., Irvin A.R., et al. Notch-ligand expression by NALT dendritic cells regulates mucosal Th1- and Th2-type responses. Biochem Biophys Res Commun 2012, 418:6-11.
75. Schleimer R.P., Kato A., Kupermann D., Arila P.C. Epithelium at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007, 120:1279-1284.
76. Newport M.J. The genetic regulation of infant immune responses to vaccination. Front Immunol 2015, 6:1-5.
77. Asanuma H., Zamri N.B., Sekine S.I., Fukuyama Y., Tokuhara D., Gilbert R.S., et al. A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 2012, 30:803-812.
78. Putz R., Pabst R. Sobotta atlas of anatomy. 3 2008, Elsevier, Munich. 14th ed.